Clinical Trial Update: Ulixertinib in People With Histiocytic Neoplasms [Phase 2]

View source ↗

Summary

This clinical trial update indicates Ulixertinib is being studied in histiocytic neoplasms in Phase 2 and the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Histiocytic Neoplasms

Drugs mentioned

• Ulixertinib (ulixertinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Histiocytic Neoplasms | Phase 2 | Status: RECRUITING